Burzynski Research Institute Reports Decrease in Net Loss and Increased Total Assets

Burzynski Research Institute, Inc. reported its financial results for the three months ending May 31, 2025, revealing a net loss of approximately $331,451, a decrease from a net loss of $371,332 during the same period in 2024. The company’s total operating expenses for the quarter were $331,451, down from $371,332 in the previous year, primarily due to a significant reduction in general and administrative expenses, which fell by 58% to $61,179. This decrease was attributed to lower professional fees and reduced reporting requirements from regulatory agencies. Research and development expenses increased by 20% to $270,272, reflecting higher personnel and facility costs as well as additional research-related expenses imposed by the FDA.

The company’s total assets as of May 31, 2025, stood at $1.52 million, a notable increase from $847,000 at the end of February 2025. Current liabilities also rose significantly to $71,237 from $42,484, driven by increases in accounts payable and accrued liabilities. The stockholders’ equity deficit widened to $69,716 from $41,637, primarily due to the net loss incurred during the quarter. The company continues to rely heavily on funding from Dr. S.R. Burzynski, who has financed operations through his medical practice, as the company has not generated significant revenue since its inception.

In terms of operational developments, Burzynski Research Institute remains focused on its research and development of Antineoplaston drugs for cancer treatment. However, the company is currently under a full clinical hold by the FDA, which prevents it from enrolling new patients in clinical trials. This hold has been in place since April 2016, and the company has not received FDA approval for any of its investigational drugs. The company’s research activities are governed by a Research Funding Agreement with Dr. Burzynski, which has been extended until February 28, 2026, but is contingent on his continued ownership of a majority of the company’s shares.

Looking ahead, the company estimates it will require approximately $900,000 for the remainder of the fiscal year ending February 28, 2026. While it anticipates continued funding from Dr. Burzynski, there is no guarantee that this support will persist. The company has indicated that if funding ceases, it may be forced to cease operations unless alternative financing can be secured. The management has expressed concerns regarding the sustainability of operations without adequate funding, emphasizing the need for additional capital through equity or debt financing to cover operating costs and achieve positive cash flow in the future.